MedTrace Logo

Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer

NCT01606358 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2014-08-11

No results posted yet for this study

Summary

In patients with an ovarian cancer, the treatment is currently based on surgery and chemotherapy.

The impact of chemotherapy on the expansion and functional abilities of Vgamma9Vdelta2 T cells has never been evaluated.

The long term goal is to give a rational to combine conventional treatment of ovarian cancer with immunotherapy based on Vgamma9Vdelta2 T cells.

Conditions

Interventions

DRUG

Carboplatin and / or taxol chemotherapy

Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Bruno Laviolle, MD PhD · Rennes University Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2016-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01606358 on ClinicalTrials.gov